Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Alector downgraded to Underperform at BofA after Alzheimer’s trial miss
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
Vigil Neuroscience initiated with an Outperform at William Blair
William Blair initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating and $18.67 fair value estimate. Vigil is developing a ...